开塞露纳肛联合膀胱理疗对显性产后尿潴留效果观察

目的:探讨开塞露纳肛联合膀胱理疗法对显性产后尿潴留的临床效果。方法:选取某院经阴道分娩符合显性产后尿潴留诊断标准的患者60例,按照随机数字表法分为研究组和对照组,每组30例。研究组采用开塞露纳肛联合膀胱理疗法,对照组采用常规诱导排尿法。比较2组患者护理后排尿时间、膀胱残余尿量、留置尿管率、临床总有效率及分娩后平均住院时间。结果:研究组排尿时间、膀胱残余尿量、留置尿管率、分娩后平均住院时间均低于对照组,临床总有效率高于对照组,组间比较,差异均有统计学意义(P<0.01)。结论:开塞露纳肛联合膀胱理疗法对显性产后尿潴留临床护理效果确切,可显著缩短排尿时间,提高排尿质量,值得临床推广。

不同膀胱理疗时机在宫颈癌术后发生尿潴留患者中的应用

目的探讨不同膀胱理疗时机在宫颈癌术后发生尿潴留患者中应用的效果。方法将70例宫颈癌术后患者分为实验组38例和对照组32例,实验组在术后第5天开始采取膀胱理疗,对照组于术后第10天拔尿管当天采取膀胱理疗。观察2组患者拔除尿管后的膀胱残余尿量。结果实验组患者膀胱残余尿量,>100ml者较对照组少(p<0.05)。结论宫颈癌术后第5天开始采取膀胱理疗有利于减少术后尿潴留的发生率。

膀胱理疗仪结合康复护理技术对宫颈癌术后患者膀胱功能及生命质量的影响

目的探究膀胱理疗仪结合康复护理技术对宫颈癌术后患者膀胱功能及生命质量的影响。方法选取2019年9月至2020年12月厦门大学附属妇女儿童医院收治的66例宫颈癌术后患者作为研究对象,采用随机数字表法将患者分为对照组和观察组,每组33例。对照组采用康复护理技术,观察组在对照组基础上联合膀胱理疗仪,比较两组的膀胱功能和生命质量。结果观察组的残余尿量少于对照组,尿管留置时间短于对照组,自解小便率高于对照组,差异均有统计学意义(P<0.05);观察组各维度生命质量评分均高于对照组(P<0.05)。结论膀胱理疗仪结合康复护理技术应用于宫颈癌术后患者中可促进膀胱功能改善,提升其生命质量。

膀胱理疗联合新斯的明促进妇科术后患者排尿的临床效果

目的探讨膀胱理疗联合新斯的明治疗妇科术后排尿困难的临床效果。方法选取2020年12月至2022年12月南昌三三四医院收治的90例妇科术后排尿困难患者作为研究对象,按照随机数字表法分为对照组(30例)、研究A组(30例)和研究B组(30例)。对照组术后常规予以止血、补液、抗感染等对症治疗,研究A组在对照组的基础上给予膀胱理疗,研究B组在研究A组的基础上,尿管拔除前予以新斯的明肌内注射。比较三组患者的排尿情况、治疗前后尿动力学指标及临床治疗效果。结果研究B组的膀胱残余尿量少于对照组和研究A组,自主排尿恢复时间短于对照组和研究A组,差异有统计学意义(P<0.05);研究A组的膀胱残余尿量少于对照组,自主排尿恢复时间短于对照组,差异有统计学意义(P<0.05)。研究B组治疗后的尿量(UV)、最大尿流率(MFR)和相对排尿阻力(RVR)高于对照组和研究A组,差异有统计学意义(P<0.05);研究A组治疗后的UV、MFR和RVR高于对照组,差异有统计学意义(P<0.05)。研究B组的治疗总有效率高于对照组,差异有统计学意义(P<0.017)。结论使用膀胱理疗联合新斯的明治疗妇科术后排尿困难患者,可有效改善膀胱功能和尿动力学指标,有较好的治疗效果。

新斯的明联合膀胱区理疗及肛门应用开塞露治疗产后尿潴留

目的：观察新斯的明联合膀胱区理疗及肛门应用开塞露治疗产后尿潴留的临床效果。方法：本次研究对象均选自2014年1~12月我院收治的产后尿潴留产妇62例,分为两组,单纯给予对照组新斯的明,研究组予以新斯的明联合膀胱区理疗及开塞露纳肛,观察两组的临床效果。结果：治疗后,研究组首次排尿时间及临床总有效率优于对照组,组间比较差异显著,存在统计学意义（P〈0.05）。结论：新斯的明联合膀胱区理疗及肛门应用开塞露治疗产后尿潴留的临床效果较为显著,能够有效缩短产妇排尿的时间,加快宫缩,值得在临床上推广。

新斯的明联合膀胱区理疗及肛门应用开塞露治疗产后尿潴留56例

目的探讨新斯的明联合膀胱区理疗及肛门应用开塞露治疗产后尿潴留临床疗效。方法对56例产后尿潴留的产妇应用新斯的明联合膀胱区理疗及肛门应用开塞露治疗临床观察，有效率为100％。结论新斯的明联合膀胱区理疗及肛门应用开塞露治疗可有效改善产妇产后尿潴留症状，临床治疗效果好，不良反应少，是一种简单可行的治疗方法。

The Expression and Significance of KAl1 and Ki67 in Bladder Transitional Cell Carcinoma

OBJECTIVE To explore the expression and significance of the tumor metastatic suppressor gene the KAI1 and Ki67 antigen in bladder transitional cell carcinoma （BTCC）. METHODS Two-stepped immuno-histochemical staining was used to detect the expression of the KAI1 protein and Ki67 antigen. The reverse transcription polymerase chain reaction （RT-PCR） was used to detect the KAI1 mRNA in 54 BTCC specimens and 32 normal bladder counterparts. 13-actin was the internal control. RESULTS The KAI1 protein was mainly expressed on cell membranes at cell-to-cell borders, with uniform and continuous staining in normal bladder transitional epithelium. However, the number of positive-staining cells was greatly decreased in BTCC epithelium, and with an increase in the stage and Grade and appearance of lymph node metastasis the staining was non-uniform and discontinuous. The Ki67 antigen was expressed in the nucleus, and with an increase in the stage and Grade and appearance of lymph node metastasis, the Ki67 expression increased. The Ki67 antigen was negatively related to the expression of KAI1 （P〈0.01）.The expression level of KAI1 mRNA was much greater in normal bladder transitional epithelium compared to BTCC, moreover, with an increase in the Grade, infiltration depth and appearance of lymph node metastasis, the expression of KAI1 mRNA was reduced. CONCLUSION The expression of KAI1 protein may be used as a prognostic marker to indicate the degree of infiltration and metastasis. Measurement of KAI1 and Ki67 expression together may be helpful in evaluating the metastatic potential and prognosis of BTCC patients.

PERITUMORAL CYSTIC MENINGIOMA:REPORT OF SIX CASES AND REVIEW OF LITERATURES

Objective Cystic meningiomas are quite rare. There is a great controversy concerning the management of the cystic wall. We reported six peritumoral cystic meningiomas and reviewed the literature to discuss the management of the cystic wall. Methods Six cases of peritumoral cystic meningiomas were retrospectively analyzed. Results Gadolinium-enhanced Tl-weighted magnetic resonance imaging scans disclosed the solid tumor enhancement in 3 cases, the cystic wall enhancement in 2 cases. One case only showed the cystic lesion. All the tumors were totally removed （ including the involved dura and partial cystic wall）. Histopathological examination showed 3 meningiotheliomatous meningiomas, 2 microcystic meningiomas, 1 mucoid degeneration. After operation, all the patients recovered well and demonstrated no neurological deficit. During the follow-up time, no tumor was recurrence. Conclusion Magnetic resonance imaging with contrast enhancement can provide information regarding whether surgical removal of the cystic wall is indicated. Peripheral enhancement of the cystic wall strongly indicates the presence of tumor infiltration. The removal of the entire cystic wall should be performed, excessive damage to brain be prevented.

DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMAS IN URINARY BLADDER

Objective To investigate the diagnosis and treatment of pheochromocytomas in urinary bladder and review relative literatures. Methods The clinical data of 6 cases of bladder pheochromocytoma were retrospectively analyzed. Bladder submucosal mass was detected by B-ultrasound in 6 cases, computerized tomography （CT） in 4, and cystoscopy in 3. All patients were treated with surgical operation. Results Two patients showed obvious fluctuation of blood pressure during operation. All patients were pathologically diagnosed as pheochromocytoma postoperatively. Five patients were followed up （from 3 months to 7 years） , and their blood pressure returned to normal. No patient had relapse and malignancy. Conclusion Typical hypertension during urination and hematuria constitute the chief symptoms of bladder pheochromocytoma. B-ultrasound, CT, and cystoscopy are the main methods for the localization of the lesions. Partial cystectomy or excision of the tumor is the preferred management and postoperative long-term follow-up is necessary.